Lymphoma (follicular non-Hodgkin's) - rituximab (replaced by TA137)

The clinical effectiveness and cost effectiveness of rituximab for follicular lymphoma

Summary

This guidance has been updated and replaced by Lymphoma (follicular non-Hodgkin's) - rituximab.

Guidance documents

• No documents found

Implementing this guidance

• No documents found

• How this guidance was produced
• Background information

We will consult on our review plans for this guidance in January 2005